- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals Inc stock price live, this page displays NASDAQ RYTM stock exchange data. View the RYTM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Rhythm Pharmaceuticals Inc real time stock price chart below.
What Is the Rhythm Pharmaceuticals Inc Stock Price Today?
The Rhythm Pharmaceuticals Inc stock price today is 85.63.
What Is the Stock Symbol for Rhythm Pharmaceuticals Inc?
The stock symbol for Rhythm Pharmaceuticals Inc is ""RYTM.""
What Stock Exchange Does Rhythm Pharmaceuticals Inc Trade On?
Rhythm Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Rhythm Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Rhythm Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RYTM quote. (ISIN: US76243J1051)
What Is the Rhythm Pharmaceuticals Inc Stock Price Today?
The Rhythm Pharmaceuticals Inc stock price today is 85.63.
What Is the Stock Symbol for Rhythm Pharmaceuticals Inc?
The stock symbol for Rhythm Pharmaceuticals Inc is ""RYTM.""
What Stock Exchange Does Rhythm Pharmaceuticals Inc Trade On?
Rhythm Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Rhythm Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Rhythm Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RYTM quote. (ISIN: US76243J1051)
85.63
-0.05(-0.06%)
Closed·
Pre Market
85.50-0.13(-0.15%)
·
Fair Value
An estimate of a Rhythm Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
84.72
85.93
52 wk Range
40.61
94.80
RYTM Scorecard
Full Analysis
Impressive gross profit margins
Earnings results expected in 6 days
More Info
Fair Value
An estimate of a Rhythm Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
84.7285.93
52 wk Range
40.6194.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RYTM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Rhythm Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
104.57
Upside
+22.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price movements are quite volatile
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Rhythm Pharmaceuticals Inc Company Profile
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Rhythm Pharmaceuticals reported Q1 2025 GAAP EPS of -$0.81, missing estimates of -$0.6734; revenue fell short at $37.72M vs $40.7M forecast
- Net product revenues grew 45% YoY to $11.7M; company ended Q1 with $314.5M cash, projecting runway into 2027
- Preparing Q3 filing for cetmelanotide in acquired hypothalamic obesity following positive Phase III results
- FY2025 revenue forecast at $183.41M, rising to $290.95M for FY2026; non-GAAP operating expenses projected $285M-$315M
- Stock rose 0.59% pre-market despite earnings miss; analysts target $65-$94 range, suggesting potential upside
Last Updated: 07/05/2025, 14:42
Read Full TranscriptCompare RYTM to Peers and Sector
Metrics to compare | RYTM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRYTMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −32.3x | −1.7x | −0.5x | |
PEG Ratio | −0.81 | −0.01 | 0.00 | |
Price/Book | 296.8x | 2.4x | 2.6x | |
Price / LTM Sales | 41.1x | 40.0x | 3.2x | |
Upside (Analyst Target) | 20.9% | 231.5% | 42.0% | |
Fair Value Upside | Unlock | 29.9% | 6.6% | Unlock |
Analyst Ratings
14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 104.57
(+22.12% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
-0.81 / -0.6734
Revenue / Forecast
32.70M / 40.70M
People Also Watch
FAQ
What Stock Exchange Does Rhythm Pharma Trade On?
Rhythm Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Rhythm Pharma?
The stock symbol for Rhythm Pharma is "RYTM."
What Is the Rhythm Pharma Market Cap?
As of today, Rhythm Pharma market cap is 5.62B.
What Is Rhythm Pharma's Earnings Per Share (TTM)?
The Rhythm Pharma EPS (TTM) is -2.82.
When Is the Next Rhythm Pharma Earnings Date?
Rhythm Pharma will release its next earnings report on 04 Aug 2025.
From a Technical Analysis Perspective, Is RYTM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Rhythm Pharma Stock Split?
Rhythm Pharma has split 0 times.
How Many Employees Does Rhythm Pharma Have?
Rhythm Pharma has 283 employees.
What is the current trading status of Rhythm Pharma (RYTM)?
As of 30 Jul 2025, Rhythm Pharma (RYTM) is trading at a price of 85.63, with a previous close of 85.63. The stock has fluctuated within a day range of 84.72 to 85.93, while its 52-week range spans from 40.61 to 94.80.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.